Capecitabine is an orally administered anticancer molecule widely used in the treatment of several solid tumors. It is designed as a prodrug, meaning it is converted inside the body into its active form, allowing for targeted anticancer activity while supporting outpatient, oral-based treatment regimens.
At the molecular level, Capecitabine is metabolized through a series of enzymatic steps to form 5-fluorouracil (5-FU), a well-established cytotoxic agent. This conversion occurs preferentially in tumor tissue, where enzyme levels are higher, helping to concentrate anticancer activity at the site of disease while reducing systemic exposure.
Because Capecitabine relies on predictable metabolic activation, molecular stability, purity, and formulation consistency are essential. These characteristics directly influence bioavailability, dosing accuracy, and clinical outcomes. Capecitabine has become an important molecule in modern oncology due to its flexibility, established efficacy, and suitability for long-term treatment strategies.
Prescribing Information
Prescribing information outlines approved indications, dosage schedules, administration instructions, contraindications, and safety warnings.
Clinical Trial Details
Capecitabine has been extensively studied in clinical trials for multiple cancer types. It has demonstrated efficacy both as monotherapy and in combination regimens.
Key studies include trials in colorectal cancer, breast cancer, and gastric cancer, where Capecitabine showed comparable or improved outcomes versus intravenous 5-FU–based therapies, with the added benefit of oral administration.
FDA Approval Status
Capecitabine is approved by the U.S. Food and Drug Administration for the treatment of multiple cancers, including colorectal cancer and breast cancer. It was originally marketed under the brand name Xeloda® by Roche.
Showing all 3 results
Last updated on 18-05-2026 20:54:14
Overview
- FaqWritten by:
Capecitabine is an orally administered anticancer molecule widely used in the treatment of several solid tumors. It is designed as a prodrug, meaning it is converted inside the body into its active form, allowing for targeted anticancer activity while supporting outpatient, oral-based treatment regimens.
At the molecular level, Capecitabine is metabolized through a series of enzymatic steps to form 5-fluorouracil (5-FU), a well-established cytotoxic agent. This conversion occurs preferentially in tumor tissue, where enzyme levels are higher, helping to concentrate anticancer activity at the site of disease while reducing systemic exposure.
Because Capecitabine relies on predictable metabolic activation, molecular stability, purity, and formulation consistency are essential. These characteristics directly influence bioavailability, dosing accuracy, and clinical outcomes. Capecitabine has become an important molecule in modern oncology due to its flexibility, established efficacy, and suitability for long-term treatment strategies.
Prescribing Information
Prescribing information outlines approved indications, dosage schedules, administration instructions, contraindications, and safety warnings.
Clinical Trial Details
Capecitabine has been extensively studied in clinical trials for multiple cancer types. It has demonstrated efficacy both as monotherapy and in combination regimens.
Key studies include trials in colorectal cancer, breast cancer, and gastric cancer, where Capecitabine showed comparable or improved outcomes versus intravenous 5-FU–based therapies, with the added benefit of oral administration.
FDA Approval Status
Capecitabine is approved by the U.S. Food and Drug Administration for the treatment of multiple cancers, including colorectal cancer and breast cancer. It was originally marketed under the brand name Xeloda® by Roche.